AstraZeneca signed a licensing agreement for Dizal Pharmaceutical’s EGFR exon 20 insertion drug Zegfrovy (sunvozertinib), paying $600 million upfront and making the deal worth up to $1.5 billion tied to development and sales milestones. AstraZeneca will gain worldwide rights to develop and commercialize Zegfrovy. The agreement follows positive phase 3 WU-KONG28 data in first-line NSCLC with EGFR exon 20 insertion mutations, where Dizal reported superior progression-free survival versus platinum-doublet chemotherapy and highlighted response-rate improvements. AstraZeneca’s move expands its EGFR franchise with an oral targeted therapy option designed for a mutational subgroup with limited alternatives. For the sector, the headline is deal mechanics plus timing: AZ secured global rights after a NEJM-published phase 3 signal, reflecting how quickly large companies are translating readouts into commercial control.